3 results
The SyncAV Post-Market Trial will evaluate changes in LV end-systolic volume (LVESV) between baseline (before CRT implant) and 12 months (post-randomization) in patients with CRT devices programmed with SyncAV compared to patients with CRT devices…
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…
Main Objective: To assess the effects of OCA in patients with PBC on: -Serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint -SafetySecondary Objectives:To assess the effects of OCA in patients with PBC on:-…